..........................................................................................................................

TECHNOLOGIES
If you visit this page through a search engine....jump to the top page

 

Following technologies are available for license. Please contact Dr Matsuoka for further information.

  • Methods to evaluate Abeta-lowering agents using wildtype mice

Provisional application, filed August 12, 2005.

Contact for detail.

 

  • Sequestration of Abeta in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases

Patent no: WO03051374

The present invention describes a method of administering an Abeta-binding agent or drug which has affinity for amyloid beta (Abeta) in the periphery (blood) and reducing Abeta levels in the brain without the need for the agent or drug to enter the brain itself. The Abeta-binding agents utilized in the methods of the invention are preferably non-immunomodulating agents (e.g., antigenic peptides or antibodies) and bind to Abeta in the periphery, or blood. Such compounds do not significantly cross the blood/brain barrier, and yet they lower amyloid (Abeta) levels in the brain, thereby serving as safer, therapeutic and prophylactic treatments against diseases associated with Abeta in the brain, e.g., Alzheimer's Disease and amyloid angiopathy, as well as against other AD-related amyloidoses.

 

Other patents will be available for licensing in the near future.

 

 

..........................................................................................................................